Hemab Therapeutics Quarterly Cash Flow Statement
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
31.62+0.73 (+2.36%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Hemab Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Hemab Therapeutics generated -$22.6 million of operating cash flow and spent $23,000 on capital expenditures. That left free cash flow of -$22.7 million.
Summary generated from market data by MetaCap's automated system. Methodology
Hemab Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -24.15M | -22.69M | -12.21M | -15.31M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 75.00K | 73.00K | 77.00K | 75.00K |
| Change in Working Capital | 550.00K | -52.00K | -2.32M | 2.88M |
| Operating Cash Flow | -22.64M | -21.58M | -15.33M | -13.03M |
| Capital Expenditures | -23.00K | -112.00K | 0 | -16.00K |
| Investing Cash Flow | -107.44M | -15.85M | 21.50M | -5.99M |
| Financing Cash Flow | 317.58M | -460.00K | -30.00K | -29.00K |
| Net Change in Cash | 187.51M | -38.11M | 6.14M | -19.06M |
| Free Cash Flow | -22.66M | -21.70M | -15.33M | -13.05M |
This table shows 4 quarterly periods of Hemab Therapeutics's cash flow statement, from Q2 2026 back to Q? 2025, across 9 line items including net income, depreciation & amortization, change in working capital. Values in USD; B = billions, M = millions. Fiscal periods follow COAG's reporting calendar. What is a cash flow statement?